Abstract. Induced pluripotent stem (iPS) cells derived from disease patients are an invaluable resource for biomedical research and may provide a source for replacement therapies. In this study, we have generated iPS cells from Asian patients with chronic degenerative diseases of the nervous system, including spinal muscular atrophy (SMA), Parkinson disease (PD) and amyotrophic lateral sclerosis (ALS) by transduction with four factors (KLF4, SOX2, OCT4 and c-MYC). All of the iPS cells showed pluripotency similar to that of human embryonic stem cells (hESCs) and were able to differentiate into various somatic cell types in vitro and in vivo. Furthermore, the iPS cells also can be committed to differentiate into neural cells, the cell type that is affected in chronic degenerative diseases. Therefore, the patient-specific iPS cells we generated offer a cellular model in which to investigate disease mechanisms, discover and test novel drugs and develop new therapies for chronic neurodegenerative diseases.
S
pinal muscular atrophy (SMA) is caused by mutations in the survival motor neuron 1 gene (SMN1) [1, 2] that result in the selective degeneration of lower α-motor neurons [3] . Clinically, the onset of SMA type 1 occurs around the sixth month of life, and death due to respiratory failure often occurs before the age of 2 years [4] . Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder in which motor neuron loss in the spinal cord and motor cortex leads to progressive paralysis and death [5] . Parkinson disease (PD) is the second most common chronic progressive neurodegenerative disorder and is characterized primarily by the major loss of nigrostriatal dopaminergic neurons [6] ; however, the majority of cases are sporadic and are not linked to a known genetic mutation.
Induced pluripotent stem (iPS) cells have pluripotency similar to that of embryonic stem (ES) cells [7, 8] . Several studies have reported the directed differentiation of iPS cells into a variety of functional cell types in vitro, and the cell therapeutic effects of implanted iPS have also been documented [9, 10] . The derivation of patient-specific iPS cells and their subsequent differentiation into specific cell types would provide experimentally accessible patient-specific in vitro models.
Here, we demonstrate that iPS cells can be produced using skin fibroblasts from SMA, ALS and PD patients of Asian origin. These patient-specific iPS cells possess a gene expression signature similar to that of human ES cells. Most importantly, these iPS cells can be directed to differentiate into neural cells, the cell type implicated in chronic degenerative diseases of the nervous system. Therefore, it represents a powerful tool for studying the disease mechanisms of chronic degenerative diseases of the nervous system, novel drug discovery and the development of new therapies; most importantly, this tool expands the resource bank for these diseases.
Materials and Methods

Derivation of patient-specific fibroblasts
After obtaining the informed consent of the patients and the approval of the Ethics Committee of The Third Affiliated Hospital of Guangzhou Medical College, dermal biopsies were taken from patients (SMA, female fetus aborted at 21 gestational weeks; ALS, 54-year-old male; PD, 56-year-old male). Fibroblasts were generated from explants of 3-mm dermal biopsies using protocols approved by the Institute of Gynecology and Obstetrics and The Third Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China. After 1 or 2 weeks, fibroblast outgrowths from the explants were passaged with trypsin and frozen.
Cell culture
Human fibroblasts and 293T cells were cultured in fibroblast medium (Dulbecco's modified Eagle's medium (DMEM) supplemented with 15% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA), 1 mmol/l glutamine (Gibco, Carlsbad, CA, USA) and 1% nonessential amino acids (NEAAs) (Gibco). hESCs and iPS cells were cultured in hESCs medium (knockout Dulbecco's modified Eagle's medium (DMEM) (Gibco) supplemented with 15% knockout serum replacement (SR) (Gibco), 5% FBS (Gibco), 2 mmol/l L-glutamine (Gibco), 0.1 mmol/l 2-mercaptoethanol (Gibco), 0.1 mmol/l nonessential amino acids (NEAAs) (Gibco), 50 units/ml penicillin (Gibco), 50 mg/ml streptomycin (Gibco), 8 ng/ml basic fibroblast growth factor (bFGF) (Invitrogen, Carlsbad, CA, USA) and 1,000 units/ml human leukemia inhibitory factor (hLIF) (Chemicon, Temecula, CA, USA). EBs were plated onto low adherence dishes in hESC medium without bFGF.
Retroviral infection and generation of iPS cells lines
Cells were infected with viral supernatants generated by the transfection of 293T cells using Lipofectamine 2000 (Invitrogen) with retroviral vectors containing cDNAs encoding human OCT4, SOX2, KLF4 and c-MYC. Two successive rounds of infection were performed (12 h each); 10 µg/ml polybrene (Sigma, St. Louis, MO, USA) was added to increase infection efficiency. After the second round of infection, the tissue culture medium from the transduced cells was exchanged for fibroblast medium. Infection efficiency was monitored separately and was close to 100%, as demonstrated by cotransduction with green fluorescent protein (GFP) expressing vectors. On day 3 or 4, the cells were trypsinized, and 5×10 5 cells were seeded onto a layer of mouse embryonic fibroblast (MEF) feeders in a 10-cm culture dish with hESC medium. The medium was changed every day. From days 16-20, colonies that were visible to the naked eye and identifiable as hESC-like were picked mechanically and expanded in hESC medium on feeders. After 4-5 days of culture, colonies were mechanically dispersed into 2-3 small clumps using a micropipette. The clumps were then transferred to a fresh MEF feeder layer. These cells were again mechanically dissociated during the initial passages. After 5 passages, they were incubated in 1 mg/ ml collagenase IV (Gibco) for 20-25 min before further culture on freshly prepared feeders. Cells were routinely passaged every 4-5 days, and the medium was changed every day.
Alkaline phosphatase activity (AP) staining and immunohistochemistry
For AP staining, cells were fixed with 90% alcohol for 2 min and washed three times with PBS and stained with BCIP/NBT (San Francisco, CA, USA) for 30 min in the dark. For immunohistochemistry, cells were fixed in 4.0% paraformaldehyde for 20 min, permeabilized with 0.5% Tween-20 for 30 min, incubated with primary antibody overnight and incubated with secondary antibodies (Alexa Fluor, Invitrogen) for 1 h. The cells were imaged with an inverted confocal microscope. The primary antibodies used in this study were SSEA-3 (1:100, Chemicon), SSEA-4 (1:100, Chemicon), TRA1-60 (1:200, Chemicon), TRA1-81 (1:500, Chemicon), OCT4 (1:500, Abcam, Cambridge, MA, USA), alpha-fetoprotein (AFP) (1:500, Chemicon), nestin (1:100, Millipore, Temecula, CA, USA), alpha-smooth muscle actin (SMA) (1:500, Chemicon) and TuJ1 (1:500, Millipore). Nuclear staining was performed with 4, 6-diamidino-2-phenylindole (DAPI).
DNA isolation and PCR analysis
Total DNA was extracted using the Qiagen DNeasy Tissue Kit (Qiagen, Berlin, Germany). The extracted DNA was used as a template to amplify 16 different genetic loci using a Promega PowerPlex 16 System kit (Promega, Madison, WI, USA). The SMN gene sequence was analyzed in SMA fibroblasts and SMA-iPS cells. Capillary electrophoresis was carried out on an automated ABI 3100 Genetic Analyzer (Applied Biosystems, Foster, CA, USA). Human leukocyte antigen (HLA) typing (e.g., HLA-A, HLA-B, HLA-Bw, HLA-DR and HLA-DRw) was performed by PCR as described by Sun et al. [11] .
Analysis of gene expression
Total RNA was isolated from fibroblasts and iPS cells using a TRIzol kit (Invitrogen). A PrimeScript RT Reagent Kit (Perfect Real Time) was used to synthesize cDNA from 0.5mg RNA (TaKaRa, Otsu, Japan). Quantitative PCR was performed with SYBR Premix Ex Taq TM II (TaKaRa) in an Applied Biosystems 7500 machine. Semiquantitative PCR was performed to detect the expression of endogenous and retroviral transgenic recombinant pluripotency genes, using the primers in Table 1 .
Karyotype analysis
iPS cells were obtained after every 10 passages for chromosome analysis as described by Sun et al. [11] . After Giemsa staining, at least 20 cells were examined in each group for chromosome analysis.
Differentiation of iPS cells in vitro
To investigate the differentiation of iPS cells in vitro, all iPS cells and hESC colonies were generated from the feeder layers following 1 mg/ml collagenase IV (Gibco) treatment. The suspension was cultured on bacterial culture plates to allow aggregation and to prevent adherence to the plate. The embryonic body (EB) culture medium was changed every other day. After suspension culture for 5 days, EB formations were examined. The EBs were transferred to 0.1% gelatin-coated culture dishes for spontaneous differentiation. After 14 days of differentiation, immunostaining was performed using antibodies against AFP (endoderm) (1:500, Chemicon), SMA (mesoderm) (1:500, Chemicon) and nestin (ectoderm) (1:100, Millipore).
Teratoma formation from iPS cells
The colonies were divided into 300-400 small colonies and subcutaneously injected into the inguinal grooves of 6-week-old males with severe combined immunodeficiency (SCID) mice (two or more mice per cell line). At four weeks after injection, the tumors could be observed, and eight weeks later, the resultant tumors were removed, fixed for 4-8 h in 4% paraformaldehyde and embedded in paraffin. After staining with hematoxylin and eosin, the sections were examined under a light microscope for the presence of tissues derived from the three germ layers.
Results
Generation of iPS cell lines
We infected fibroblasts at passage 2 to 3 with retroviruses encoding SOX2, KLF4, OCT4 and c-MYC. Infection efficiency was measured by parallel transduction with retroviruses encoding GFP. Within one week, hundreds of colonies composed of rapidly dividing cells had appeared; these had a granular morphology not characteristic of ES cells. However, one week later, a small number of colonies with hESC morphology were identified. The SMA-iPS cells appeared approximately 12 days after infection, and ALS-iPS cells and PD-iPS cells appeared around at 20 to 25 days after infection. All hESC-like colonies were picked manually and expanded clonally (Fig. 1A-D) .
DNA and karyotype analyses
The 16 short tandem repeat (STR) loci were identical between the fibroblasts and related iPS cells and confirmed that the iPS cell lines were genetically matched to their parental somatic lines, ruling out the possibility of cross contamination from existing cultures of human pluripotent cells, as described in Table 2 . The HLA typing loci of the fibroblasts and the iPS cells were also identical, as described in Table 3 . The SMN sequence in both SMA fibroblasts and SMA-iPS cells lacked exon 7 (SMNΔ7) ( Fig. 2A-B) . Using semiquantitative PCR, all the iPS cells lines showed expression of the relevant reprogramming factors assumed by endogenous loci (e.g., OCT4, SOX2, KLF4 and c-MYC); in contrast, the retroviral transgenes were largely silenced in the iPS cell lines (Fig. 2C) . Quantitative real-time PCR indicated that the expression of pluripotency-related genes (e.g., OCT4, SOX2, NANOG, REX1, KLF4 and c-MYC) in iPS cells was similar to that of normal hESCs and much higher than that in the initial fibroblast cells (Fig. 2D-F) . SMA-iPS cells exhibited the normal 46, XX karyotype (Fig. 2G) , and the ALS-iPS and PD-iPS cells exhibited normal 46, XY karyotypes (Fig. 2H-I ).
Characterization of cell lines
All iPS cells lines exhibited strong AP activity and expressed several hESC-associated antigens (SSEA-3, SSEA-4, TRA1-60, TRA1-81 and NANOG) (Fig. 3) . All iPS cell lines were able to form EBs. Each line expressed the endodermal marker alpha-fetoprotein (AFP), the ectodermal marker nestin and the mesodermal marker smooth muscle actin (SMA) (Fig. 4A) . Typical neural tube-like rosettes formed after approximately 14 days of neural differentiation. On day 24, neurons extended out of the cluster with long axons. These processes were evaluated by immunocytochemistry for TuJ1 (Fig. 4B ). Teratomas were observed at 4-10 weeks. Histological examination revealed that the teratomas contained tissues from all three embryonic germ layers, including neural tube-like cells (ectoderm), fat cells (mesoderm) and glandular tissue (endoderm) (Fig. 4C) .
Discussion
Induced pluripotent stem (iPS) cells have emerged rapidly as a new tool since their first description in 2007; these cells are popular because they can overcome several of the complications associated with somatic cell nuclear transfer and ES cell fusion, such as legal, ethical, regulatory and economic obstacles [12] . Currently, iPS cell-based research has mainly focused on patients diagnosed with "patient-specific" diseases, such as ALS, SMA, PD and Duchenne muscular dystrophy (DMD) [13] [14] [15] [16] .
Here, we demonstrated that iPS cells can be derived from skin fibroblasts from Asian patients with chronic degenerative diseases of the nervous system, including SMA, ALS and PD. These patientspecific iPS cells exhibited AP activity, expressed hESC-associated antigens and were able to differentiate into the three embryonic germ layers in vitro and vivo. Furthermore, the iPS cells maintained normal karyotypes after long periods of culture in vitro. These results showed that we established the iPS cells successfully. However, we found that the SMA fibroblasts obtained from a fetus aborted at 21 gestational weeks grew faster than those obtained from the adult ALS and PD patients; furthermore, the SMA-iPS cells first appeared approximately 12 days after infection, more rapidly than the ALS-iPS and PD-iPS cells. We conjecture that the patient age is an important factor in the efficiency of infection.
Previous studies have reported that iPS cells have the ability to differentiate into neural progenitors [17] , motor neurons [13] and dopaminergic neurons [15] . Our study proved that iPS cells derived from several different patients could differentiate into neural cells, as evaluated by immunocytochemistry for nestin and TuJ1. Although the fibroblasts were isolated from patients with chronic degenerative nervous system diseases, we found that the derived iPS cells were able to differentiate into neural cells with kinetics similar to those of human embryonic stem cells. Thus, we presume that these genetic defects do not significantly affect iPS differentiation. These patient-specific iPS cells carry the precise genetic information associated with the patient's pathology. Overall, the iPS cell disease models we generated are promising tools with which to investigate disease mechanisms, discover and test novel drugs and develop new therapies for chronic neurodegenerative diseases. 
